Literature DB >> 34214644

Development of natural products for anti-PD-1/PD-L1 immunotherapy against cancer.

Myong Hak Ri1, Juan Ma2, Xuejun Jin3.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: The programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) immune checkpoint is one of the most promising therapeutic targets for cancer immunotherapy, but several challenges remain in current anti-PD-1/PD-L1 therapy. Natural products, mainly derived from traditional medicine, could improve and expand anti-PD-1/PD-L1 therapy because of their advantages such as large diversity and multi-target effects. AIM OF THE STUDY: This review summarize natural products, raw extracts, and traditional medicines with pharmacological effects associated with the PD-1/PD-L1 axis, particularly PD-L1.
MATERIALS AND METHODS: Electronic literature databases, including Web of Science, PubMed, and ScienceDirect, and online drugs and chemicals databases, including DrugBank, ZINC, PubChem, STITCH, and CTD, were searched without date limitation by February 2021. 'Natural product or herb or herbal plant or traditional medicine' and 'PD-L1' and 'Cancer immunotherapy' were used as the search keywords. Among 112 articles identified in database searching, 54 articles are full text articles, reporting in silico, in vitro, in vivo and clinical trials. 68 articles included are review articles and grey literature such as thesis and congress abstracts.
RESULTS: Several natural products and traditional medicines have exhibited diverse and multi-functional effects including direct blockade of PD-1/PD-L1 interactions, modulation of PD-L1 expression, and cooperation with PD-1/PD-L1 inhibitors.
CONCLUSION: Natural products and traditional medicines can facilitate the development of more effective and acceptable diverse strategies for anti-PD-1/PD-L1 therapy, but further exploration of natural products and pharmaceutical techniques is required.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer immunotherapy; Natural products; PD-1; PD-L1

Mesh:

Substances:

Year:  2021        PMID: 34214644     DOI: 10.1016/j.jep.2021.114370

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  5 in total

1.  FOXO3-dependent suppression of PD-L1 promotes anticancer immune responses via activation of natural killer cells.

Authors:  Young Min Chung; Wen Bin Tsai; Pragya P Khan; Jessica Ma; Jonathan S Berek; James W Larrick; Mickey C-T Hu
Journal:  Am J Cancer Res       Date:  2022-03-15       Impact factor: 6.166

Review 2.  Advances in plant-derived natural products for antitumor immunotherapy.

Authors:  Yi Yang; Qinying Liu; Xianai Shi; Qiuhong Zheng; Li Chen; Yang Sun
Journal:  Arch Pharm Res       Date:  2021-11-09       Impact factor: 4.946

3.  Computational Investigations on the Natural Small Molecule as an Inhibitor of Programmed Death Ligand 1 for Cancer Immunotherapy.

Authors:  Geethu S Kumar; Mahmoud Moustafa; Amaresh Kumar Sahoo; Petr Malý; Shiv Bharadwaj
Journal:  Life (Basel)       Date:  2022-04-29

4.  Gross perianal embryonal rhabdomyosarcoma with severe multiple bone metastases throughout the body: a case report.

Authors:  Jing-Jing Lu; Min-Bin Chen; Xiao-Jiao Gao; Yan Zhang; Yuan-Yuan Liu; Yang Yong; Ping Li
Journal:  J Int Med Res       Date:  2022-03       Impact factor: 1.671

Review 5.  The Role of Tumor Microenvironment in Invasion and Metastasis of Esophageal Squamous Cell Carcinoma.

Authors:  Shuyue Zheng; Beilei Liu; Xinyuan Guan
Journal:  Front Oncol       Date:  2022-06-22       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.